SNRI for Anxiety and Depression
For adults with co-occurring anxiety and depression, duloxetine is the preferred SNRI, with venlafaxine extended-release as an alternative, while SSRIs remain first-line therapy overall. 1
Medication Selection Algorithm
First-Line Approach
- SSRIs should be tried first before SNRIs for most patients with comorbid anxiety and depression 2
- SNRIs are appropriate when SSRIs have failed or are not tolerated 1
SNRI Selection Within Class
Duloxetine is the preferred SNRI because:
- Only SNRI with FDA approval for generalized anxiety disorder in both adults and children (≥7 years) 1
- Proven efficacy in both depression and generalized anxiety disorder 3
- Simple once-daily dosing (60 mg/day) 3
- No clinically significant blood pressure or cardiac conduction changes 3
- Effective for comorbid chronic pain syndromes 3, 4, 5
Venlafaxine extended-release is the alternative:
- Efficacy demonstrated in multiple anxiety disorders and depression 1, 6
- Requires 2-4 weeks to titrate to therapeutic dose (150-225 mg/day) 3
- Major limitation: dose-dependent hypertension and potential cardiac conduction abnormalities 3, 1, 4
- Higher suicide risk compared to other SNRIs 1
- More withdrawal symptoms than duloxetine 1
Critical Safety Considerations
Duloxetine-Specific Warnings
- Discontinue immediately if: jaundice, hepatomegaly, elevated transaminases, or severe skin reactions (Stevens-Johnson syndrome, erythema multiforme) develop 1
- Start at 30 mg daily for 1 week before increasing to 60 mg to reduce nausea 3
Venlafaxine-Specific Warnings
- Monitor blood pressure at each visit - increases occur in dose-dependent manner 3, 1
- Use with caution in cardiac disease 3
- Must taper slowly when discontinuing to avoid withdrawal syndrome 3, 1
Class-Wide SNRI Precautions
- Monitor for suicidal ideation (especially ages ≤24 years) 1
- Check blood pressure and pulse regularly 1
- Common adverse effects: nausea, dry mouth, diaphoresis, dizziness, insomnia, decreased appetite 1
- Contraindicated with MAOIs - risk of serotonin syndrome 1
Dosing and Monitoring
Duloxetine
- Start: 30 mg once daily for 1 week
- Target: 60 mg once daily
- Maximum: 60 mg once daily (higher doses not more effective) 3
- Adequate trial: 6-8 weeks at target dose 3
Venlafaxine Extended-Release
- Start: Low dose, titrate gradually
- Target: 150-225 mg/day
- Titration period: 2-4 weeks 3
- Adequate trial: 6-8 weeks at target dose
Essential Monitoring
- Height, weight, pulse, blood pressure at each visit 1
- No routine laboratory monitoring required for duloxetine 3
- Assess response within 1-2 weeks of initiation 2
- Modify treatment if inadequate response after 6-8 weeks 2
Duration of Treatment
- Continue for 4-9 months after satisfactory response for first episode 2
- Longer duration needed for patients with ≥2 prior episodes 2
- Taper slowly when discontinuing - both SNRIs cause discontinuation syndrome 1
Special Populations
Children and Adolescents (6-18 years)
- Duloxetine is FDA-approved for GAD in children ≥7 years 1
- SNRIs can be considered for social anxiety, generalized anxiety, separation anxiety, and panic disorder 1
- Parental oversight of medication regimens is paramount 1
Comorbid Chronic Pain
- Duloxetine is specifically advantageous for patients with comorbid fibromyalgia, neuropathic pain, or chronic pain syndromes 3, 7, 4, 5
Common Pitfalls to Avoid
Don't use venlafaxine immediate-release - requires multiple daily doses due to short half-life; use extended-release formulation 1
Don't ignore blood pressure with venlafaxine - this is a dose-dependent and potentially serious adverse effect 3, 1
Don't abruptly discontinue SNRIs - both duloxetine and venlafaxine require slow taper to avoid withdrawal syndrome 3, 1
Don't continue ineffective treatment - if no response after 6-8 weeks at therapeutic dose, switch medications 2
Don't overlook hepatic monitoring with duloxetine - while routine monitoring isn't required, discontinue immediately if signs of liver dysfunction appear 3, 1